Today is July 02, 2024.
All times in Eastern Daylight Time.
-
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company received and accepted an unsolicited offer from an institutional ... more »
-
Eutelsat Group Achieves Platinum Score in Space Sustainability Rating
PARIS--(BUSINESS WIRE)--Eutelsat Group achieves Platinum Score in Space Sustainability Rating more »
-
Germans Trias i Pujol Hospital in Spain Launches Telehealth and Remote Patient Management Program Using Masimo W1® Medical Watches and Radius VSM™ Wearable Continuous Vital Signs Monitors
BARCELONA, Spain--(BUSINESS WIRE)--Germans Trias i Pujol Hospital in Spain is launching a breakthrough telehealth program using Masimo wearable technology and Hospital Automation™. more »
-
Ferguson Files Form 8-K
WOKINGHAM, England--(BUSINESS WIRE)--On May 31, 2024, Ferguson plc (the "Company") filed a Form 8-K with the U.S. Securities and Exchange Commission ("SEC"). It is available on the SEC's website at... more »
-
Discover® Global Network Study Shows 85% of Consumers are Less Likely to Interact with a Business Due to a Poor Payment Experience
RIVERWOODS, Ill.--(BUSINESS WIRE)--Discover Global Network®, a leading global payment network, released the first portion of the 2024 Payment State of the Union (PSOU), one of the most comprehensiv... more »
-
WEBTOON Entertainment Announces Public Filing of Registration Statement for Proposed Initial Public Offering
LOS ANGELES--(BUSINESS WIRE)--WEBTOON Entertainment Inc. (“WEBTOON” or “the Company”), a leading global entertainment company and home to some of the world’s largest storytelling platforms, today a... more »
-
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bis... more »
-
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
PHILADELPHIA--(BUSINESS WIRE)--Belantamab Mafodotin combo reduced the risk of disease progression or death by nearly 50% versus SOC combo in relapsed/refractory multiple myeloma more »
-
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that findings from the Phase II trial of its drug alisertib (TBCRC 041) were presented at the ASCO 2024 Annual Meeting. more »
-
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 s... more »
-
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 s... more »
-
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Demonstrated a Median PFS of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow mBC Following One or More Lines of Endocrine Therapy more »
|
|